Pyrido-pyrimidine derivative CYC10424 inhibits glycosaminoglycan changes on vascular smooth muscle-derived proteoglycans and reduces lipoprotein binding

Journal of Cardiovascular Pharmacology

Volumn 52, Issue 5, 2008, Pages 403-412

  Ballinger, Mandy L ^a,d   Osman, Narin ^a   Wilks, Andrew F ^b   Su, Stephen ^b   Burns, Christopher J ^c   Bu, Xianyong ^c   Little, Peter J ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c Cytopia Research Ltd   (Australia)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Aorta; Endothelium; Fenofibrate; Isoproterenol; Pioglitazone; PPAR

Indexed keywords

CYC 10424; DISACCHARIDE; GLYCOSAMINOGLYCAN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; N [4 METHYL 3 [(4 PYRIDIN 3 YL PYRIMIDIN 2 YL)AMINO]PHENYL] N' PHENYLUREA; PROTEOGLYCAN; PYRIMIDINE DERIVATIVE; RECOMBINANT PLATELET DERIVED GROWTH FACTOR BB; UNCLASSIFIED DRUG; CARBANILAMIDE DERIVATIVE; N (4 METHYL 3 ((4 PYRIDIN 3 YLPYRIMIDIN 2 YL)AMINO)PHENYL) N' PHENYLUREA; N-(4-METHYL-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)PHENYL)-N'-PHENYLUREA; PLATELET DERIVED GROWTH FACTOR;

ARTICLE; ATHEROSCLEROSIS; BINDING AFFINITY; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; ELECTROPHORETIC MOBILITY; GEL MOBILITY SHIFT ASSAY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; ISOTOPE LABELING; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN SYNTHESIS; SULFATION; VASCULAR SMOOTH MUSCLE; BIOSYNTHESIS; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; SYNTHESIS;

ATHEROSCLEROSIS; CELL LINE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GLYCOSAMINOGLYCANS; HUMANS; LIPOPROTEINS, LDL; MOLECULAR STRUCTURE; MUSCLE, SMOOTH, VASCULAR; PHENYLUREA COMPOUNDS; PLATELET-DERIVED GROWTH FACTOR; PROTEIN BINDING; PROTEOGLYCANS; PYRIMIDINES;

EID: 59449095963     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31818a8907     Document Type: Article

References (49)

1. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med. 1997; 337:1360-1369.
2. Haffner SM, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229-234.
3. Ross R. The pathogenesis of atherosclerosis. N Engl J Med. 1986;314: 488-500.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med. 1999; 340:115-126.
6. Williams KJ, Tabas I. The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol. 1995;15:551-561.
7. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. Circulation. 2007;116:1832-1844.
8. Skalen K, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature. 2002;417:750-754.
9. Nakashima Y, et al. Early human atherosclerosis: accumulation of lipid and proteoglycans in intimal thickenings followed by macrophage infiltration. Arterioscler Thromb Vasc Biol. 2007;27:1159-1165.
10. Nakashima Y, Wight TN, Sueishi K. Early atherosclerosis in humans: role of diffuse intimal thickening and extracellular matrix proteoglycans. Cardiovasc Res. 2008;79:14-23.
11. Tran-Lundmark K, et al. Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation. Circ Res. 2008;103:43-52.
12. Huang F, et al. Angiotensin II increases vascular proteoglycan content preceding and contributing to atherosclerosis development. J Lipid Res. 2008;49:521-530.
13. Ballinger ML, et al. Regulation of glycosaminoglycan structure and atherogenesis. Cell Mol Life Sci. 2004;61:1296-1306.
14. Little PJ, Ballinger ML, Osman N. Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis. Vascular Health Risk Management. 2007;3:1-8.
15. Silbert JE, Sugumaran G. Biosynthesis of chondroitin/dermatan sulfate. IUBMB Life. 2002;54:177-186.
16. Figueroa JE, Vijayagopal P. Angiotensin II stimulates synthesis of vascular smooth muscle cell proteoglycans with enhanced low density lipoprotein binding properties. Atherosclerosis. 2002;162:261-268.
17. Little PJ, et al. Proteoglycans synthesized by arterial smooth muscle cells in the presence of transforming growth factor-beta1 exhibit increased binding to LDLs. Arterioscler Thromb Vasc Biol. 2002;22:55-60.
18. Dadlani H, et al. Smad and p38 MAP kinase-mediated signaling of proteoglycan synthesis in vascular smooth muscle. J Biol Chem. 2008; 283:7844-7852.
19. Nigro J, et al. Fenofibrate modifies human vascular smooth muscle proteoglycans and reduces LDL binding. Diabetologia. 2004;47:2105- 2113.
20. de Dios ST, et al. Regulation of the atherogenic properties of vascular smooth muscle proteoglycans by oral anti-hyperglycemic agents. J Diabetes Complications. 2007;21:108-117.
21. Tannock L, et al. Arterial smooth muscle cell proteoglycans synthesized in the presence of glucosamine demonstrate reduced binding to LDL. J Lipid Res. 2002;43:149-157.
22. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001; 411:355-365.
23. Kozaki K, et al. Blockade of platelet-derived growth factor or its receptors transiently delays but does not prevent fibrous cap formation in ApoE null mice. Am J Pathol. 2002;161:1395-1407.
24. Evanko SP, et al. Proteoglycan distribution in lesions of atherosclerosis depends on lesion severity, structural characteristics, and the proximity of platelet-derived growth factor and transforming growth factor-beta. Am J Pathol. 1998;152:533-546.
25. Schonherr E, et al. Platelet-derived growth factor and transforming growth factor-beta 1 differentially affect the synthesis of biglycan and decorin by monkey arterial smooth muscle cells. Arterioscler Thromb. 1993;13: 1026-1036.
26. Schonherr E, et al. Effects of platelet-derived growth factor and transforming growth factor-beta 1 on the synthesis of a large versican-like chondroitin sulfate proteoglycan by arterial smooth muscle cells. J Biol Chem. 1991;266:17640-17647.
27. Manley PW, et al. Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases. Bioorg Med Chem Lett. 2004;14:5793-5797.
28. Zimmermann J, et al. Phenylamino-pyrimidine (PAP) derivatives: a new class of potent and selective inhibitors of protein kinase C (PKC). Arch Pharm (Weinheim). 1996;329:371-376.
29. Neylon CB, et al. Intracellular pH in human arterial smooth muscle. Regulation by Na+/H+ exchange and a novel 5-(N-ethyl-N-isopropyl)-amiloride- sensitive Na(+)- and HCO3(-)-dependent mechanism. Circ Res. 1990;67:814-825.
30. Nigro J, Dilley RJ, Little PJ. Differential effects of gemfibrozil on migration, proliferation and proteoglycan production in human vascular smooth muscle cells. Atherosclerosis. 2002;162:119-129.
31. Kawakami S, et al. PPARgamma ligands suppress proliferation of human urothelial basal cells in vitro. J Cell Physiol. 2002;191:310-319.
32. Tannock LR, et al. Thiazolidinediones reduce the LDL binding affinity of non-human primate vascular cell proteoglycans. Diabetologia. 2004;47: 837-843.
33. Potter-Perigo S, et al. Altered proteoglycan synthesis via the false acceptor pathway can be dissociated from beta-D-xyloside inhibition of proliferation. Arch Biochem Biophys. 1992;297:101-109.
34. Moses J, Oldberg A, Fransson LA. Initiation of galactosaminoglycan biosynthesis. Separate galactosylation and dephosphorylation pathways for phosphoxylosylated decorin protein and exogenous xyloside. Eur J Biochem. 1999;260:879-884.
35. Calabro A, Hascall VC, Midura RJ. Adaptation of FACE methodology for microanalysis of total hyaluronan and chondroitin sulfate composition from cartilage. Glycobiology. 2000;10:283-293.
36. Templeton DM. The basis and applicability of the dimethylmethylene blue binding assay for sulfated glycosaminoglycans. Connect Tissue Res. 1988; 17:23-32.
37. Heinecke JW, et al. Superoxide-mediated modification of low density lipoprotein by arterial smooth muscle cells. J Clin Invest. 1986;77: 757-761.
38. Libby P, et al. Production of platelet-derived growth factor-like mitogen by smooth-muscle cells from human atheroma. N Engl J Med. 1988;318: 1493-1498.
39. Wasteson, A., A method for the determination of the molecular weight and molecular-weight distribution of chondroitin sulphate. J Chromatogr, 1971. 59(1): p. 87-97.
40. Fritz, T.A. and J.D. Esko, Xyloside Priming of Glycosaminoglycan Biosynthesis and Inhibition of Proteoglycan Assembly, in Proteoglycan Protocols, R.V. Iozzo, Editor. 2001, Humana Press Inc: Totowa, NJ. p. 317-324.
41. Gigli, M., et al., A comparative study of low-density lipoprotein interaction with glycosaminoglycans. Biochim Biophys Acta. 1993; 1167:211-217.
42. Camejo G. The interaction of lipids and lipoproteins with the intercellular matrix of arterial tissue: its possible role in atherogenesis. Adv Lipid Res. 1982;19:1-53.
43. Ross R. Cell biology of atherosclerosis. Annu Rev Physiol. 1995;57: 791-804.
44. Lamb DJ, Avades TY, Ferns GA. Endogenous neutralizing antibodies against platelet-derived growth factor-aa inhibit atherogenesis in the cholesterol-fed rabbit. Arterioscler Thromb Vasc Biol. 2001;21: 997-1003.
45. Rutherford C, et al. Endogenously elicited antibodies to platelet derived growth factor-BB and platelet cytosolic protein inhibit aortic lesion development in the cholesterol-fed rabbit. Int J Exp Pathol. 1997; 78:21-32.
46. Sano H, et al. Functional blockade of platelet-derived growth factor receptor-beta but not of receptor-alpha prevents vascular smooth muscle cell accumulation in fibrous cap lesions in apolipoprotein E-deficient mice. Circulation. 2001;103:2955-2960.
47. Boucher P, Gotthardt M. LRP and PDGF signaling: a pathway to atherosclerosis. Trends Cardiovasc Med. 2004;14:55-60.
48. Lassila M, et al. Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler Thromb Vasc Biol. 2004;24:935-942.
49. Battegay EJ, et al. TGF-beta induces bimodal proliferation of connective tissue cells via complex control of an autocrine PDGF loop. Cell. 1990;63: 515-524.